ANI Pharmaceuticals
ANIP
201 hedge funds and large institutions have $962M invested in ANI Pharmaceuticals in 2024 Q2 according to their latest regulatory filings, with 33 funds opening new positions, 74 increasing their positions, 62 reducing their positions, and 29 closing their positions.
459% more call options, than puts
Call options by funds: $3.16M | Put options by funds: $566K
19% more repeat investments, than reductions
Existing positions increased: 74 | Existing positions reduced: 62
14% more first-time investments, than exits
New positions opened: 33 | Existing positions closed: 29
5.12% more ownership
Funds ownership: 66.98% → 72.1% (+5.1%)
1% more funds holding
Funds holding: 199 → 201 (+2)
1% less capital invested
Capital invested by funds: $975M → $962M (-$12.9M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
Tang Capital Management
San Diego,
California
|
+$19.5M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$16.2M |
| 3 |
Millennium Management
New York
|
+$13.6M |
| 4 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
+$11.3M |
| 5 |
GACM
Global Alpha Capital Management
Montreal,
Quebec, Canada
|
+$8.84M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
-$23.1M |
| 2 |
RCMNY
Rubric Capital Management (New York)
New York
|
-$23M |
| 3 |
HIM
Hillsdale Investment Management
Toronto,
Ontario, Canada
|
-$4.38M |
| 4 |
CSS
Cubist Systematic Strategies
Stamford,
Connecticut
|
-$3.85M |
| 5 |
Jane Street
New York
|
-$2.67M |
ANIP Hedge Fund Activity: Q2 2024 in Review
201 of the 6,935 institutional investors tracked by Wall St. Rank reported a position in ANI Pharmaceuticals (ANIP) for Q2 2024, worth a combined $962M — down 1.3% from $975M a quarter earlier.
Buyers outnumbered sellers: 33 funds opened new ANIP positions and 29 closed out — a net gain of 4 holders — while 74 added to existing stakes and 62 trimmed.
The largest buyer was Tang Capital Management, adding an estimated $19.5M. The largest seller was Deep Track Capital, cutting an estimated $23.1M.
- 201 institutional investors held ANI Pharmaceuticals (ANIP) as of Q2 2024, up from 199 in Q1 2024.
- Funds reported $962M of ANI Pharmaceuticals stock for Q2 2024, down 1.3% quarter-over-quarter.
- 33 funds opened new ANI Pharmaceuticals positions in Q2 2024 and 29 closed out, a net change of +4 holders.
- The largest ANI Pharmaceuticals buyer in Q2 2024 was Tang Capital Management, an estimated $19.5M added.
- The largest ANI Pharmaceuticals seller in Q2 2024 was Deep Track Capital, an estimated $23.1M sold.
Based on aggregated 13F filings for Q2 2024.